Zybiraa 250Mg Tablet Substitute
by ES
by Others
by AYUR
by AYUR
by Others
by Others
by Others
by Others
by Others
by Others
by Others
Composition:
ABIRATERONE-250MG
Uses:
Zybiraa 250Mg Tablet is used in the treatment of prostate cancer. The detailed uses of Zybiraa 250Mg Tablet are as follows:<br/>• Treats advanced prostate cancer: Zybiraa 250Mg Tablet lowers levels of certain hormones (androgens) that fuel the growth of prostate cancer cells.<br/>• Slows cancer progression: Zybiraa 250Mg Tablet helps delay the spread and worsening of prostate cancer.<br/>• Improves overall management of prostate cancer: Zybiraa 250Mg Tablet is often used along with other medicines to enhance treatment effectiveness.<br/>
Medicinal Benefits:
Zybiraa 250Mg Tablet belongs to the group of medicines called androgen biosynthesis inhibitors, indicated in combination with prednisone or prednisolone to treat prostate cancer in adult men that have spread to other body parts. Zybiraa 250Mg Tablet contains ‘Abiraterone’ that works by stopping the body from making testosterone, thereby slowing the growth of prostate cancer. It is indicated in patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel and metastatic high-risk castration-sensitive prostate cancer (CSPC). Zybiraa 250Mg Tablet is prescribed in the early stages of the disease, where it is still responding to hormone therapy. It is used with androgen deprivation therapy (a treatment that lowers testosterone).
Zybiraa 250Mg Tablet is used to treat Prostate cancer.
Zybiraa 250Mg Tablet works by stopping the body from making testosterone, thereby slowing the growth of prostate cancer.
Prednisolone/prednisone is prescribed along with Zybiraa 250Mg Tablet to lower the chances of getting high blood pressure, fluid retention (having too much water in the body), or low blood potassium levels.
Zybiraa 250Mg Tablet should not be given along with Ra-233 (a radioactive isotope used to treat prostate cancer) due to the increased risk of bone fracture or death. If you are prescribed to take Ra-233 following treatment with Zybiraa 250Mg Tablet and prednisolone/prednisone, you must wait five days before starting treatment with Ra-233.
No, Zybiraa 250Mg Tablet cannot cure prostate cancer. However, it is used to manage advanced or metastatic prostate cancer that works by inhibiting the production of testosterone, thereby preventing the growth and spread of cancer.
No, Zybiraa 250Mg Tablet is not a chemotherapy drug. It is a hormone therapy medication, which reduces testosterone levels to help manage prostate cancer.
Yes, Zybiraa 250Mg Tablet may affect the liver. Therefore, the doctor may advise regular blood tests to monitor its effects on the liver.
For patients taking Zybiraa 250Mg Tablet liver investigations are recommended. However, the frequency may differ for each individual and can be determined by the doctor based on your medical condition.
Zybiraa 250Mg Tablet can be taken orally on an empty stomach, either 1 hour before a meal or 2 hours after the meal. Swallow it as a whole with a glass of water. Do not chew or break it.
The side effects of Zybiraa 250Mg Tablet include oedema, urinary tract infection, high blood pressure, low blood potassium, and diarrhoea. Consult the doctor if any of these symptoms persist or worsen.